GlassScriptPhysician profile
Edward Van Vooren
NPI 1770512477
$290.85
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.84 · 2020: $33.88 · 2021: $108 · 2022: $131.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Morphosys, US INC. | $35.98 | 2021-2022 | |
| Seagen INC. | $28.98 | 2020-2021 | |
| Siemens Medical Solutions USA, INC. | $23.62 | 2021 | |
| Merck Sharp & Dohme LLC | $22.50 | 2022 | |
| Epizyme, INC. | $21.69 | 2022 | |
| Servier Pharmaceuticals LLC | $21.29 | 2022 | |
| Janssen Biotech, INC. | $19.78 | 2021 | |
| Amgen INC. | $18.19 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.18 | 2021 | |
| Genmab U.S., INC. | $16.35 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.27 | 2021 | |
| Celgene Corporation | $15.80 | 2022 | |
| Eisai INC. | $15.38 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Van Vooren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.